Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

RBOT.WS vs STE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

STE Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

STE Overall Winner 6-Pillar Tally: RBOT.WS 0 – 6 STE Matrix Metrics: RBOT.WS 1 – 9 STE

As of Nov 20, 2026, STERIS plc (STE) is the stronger overall head-to-head candidate over Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of (RBOT.WS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RBOT.WS carries a Unified Composite Score of 50.1/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin), whereas STE carries 42.6/100 (HOLD) at $255.76 (23.1x Forward P/E, 19.2% operating margin).

  • Composite vs. Pillar Nuance: While RBOT.WS currently prints a higher short-term Unified Composite Score (50.1/100 HOLD vs. STE 42.6/100 HOLD), STE captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (19.2% vs. N/A operating margin) and revenue trajectory (+8.8% vs. N/A YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RBOT.WS vs STE
RBOT.WS NYSE
Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of Class A Common Stock at an exercise price of $345.00
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$0.01
-24.77% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol N/A
Unified Composite Score
50.1 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
STE NYSE Head-to-Head Winner
STERIS plc
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$255.76
+0.39% 1D
Market Cap $24.7B
TTM Revenue $6.17B
Forward P/E 23.1x
Beta / 30D Vol 0.18β · 35% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 22.0 Fund 48.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.3% over 20 days), RSI 62
RSI-14: 62.3 · SMA20: $247.16 · SMA50: $227.43

6-Pillar Scorecard Institutional Category Breakdown (RBOT.WS 0 – 6 STE)

Columns: Metric · RBOT.WS · STE
1. Valuation Multiples STE
Forward P/E N/M 23.1x
Trailing P/E N/M 30.2x
PEG Ratio N/M 2.53x
EV / Revenue N/M 4.3x
2. Growth & Scale STE
Revenue Growth (YoY) N/A +8.8%
Earnings Growth (YoY) N/A +12.9%
TTM Revenue (USD) N/A $6.17B
Market Cap N/A $24.7B
3. Profitability & Quality STE
Gross Margin N/A 44.3%
Operating Margin N/A 19.2%
Net Profit Margin N/A 13.4%
Return on Equity (ROE) N/A 11.6%
4. Balance Sheet & Cash Flow STE
Cash Generation (TTM) N/A $937M
Cash Flow Margin N/A 15.2%
Net Cash / Leverage N/A ROE $1.52B Net Debt (0.28x D/E)
Dividend Yield None (0.00%) 0.99%
5. Options & Positioning STE
Options Structure Phase UNCLASSIFIED SURGE
Current IV / %ile N/A (N/A) 30.0% (7th %ile)
Put/Call OI Skew N/A 4.50x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat STE
OpEx & R&D Intensity N/A 25.1% of Rev ($1.55B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Orthopedic, Prosthetic & Surgical Appliances & Supplies Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RBOT.WS (1) vs STE (9)
Institutional Metric RBOT.WS STE Criterion Row Edge
Market Capitalization
Scale
N/A $24.7B Larger Scale STE
Trailing P/E Ratio
Valuation
N/M 30.2x Lower Multiple STE
Forward P/E Ratio
Valuation
N/M 23.1x Lower Multiple STE
Revenue Growth (YoY)
Growth
N/A +8.8% Higher Growth STE
Operating Margin (TTM)
Profitability
N/A 19.2% Higher Margin STE
Net Profit Margin
Profitability
N/A 13.4% Higher Margin STE
Return on Equity (ROE)
Capital Efficiency
N/A 11.6% Higher ROE STE
52-Week Range Position
Momentum
0% ($0–$0) 82% ($195–$269) Stronger Trend STE
Beta / 30D Volatility
Risk Regime
N/A 0.18β · 35% Vol Lower Realized Risk STE
Unified Institutional Score
Composite Signal
50.1 / 100 (HOLD) 42.6 / 100 (HOLD) Higher Composite RBOT.WS
Trailing 12M Revenue (USD)
Operating Scale
N/A $6.17B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 44.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 2.53x PEG · 4.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $937M ($1.52B Net Debt (0.28x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon STE +66.27 pp
RBOT.WS: -67.2% · STE: -0.93%
3M Horizon STE +66.27 pp
RBOT.WS: -67.2% · STE: -0.93%
6M Horizon STE +66.27 pp
RBOT.WS: -67.2% · STE: -0.93%
1Y Horizon STE +66.27 pp
RBOT.WS: -67.2% · STE: -0.93%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RBOT.WS vs STE. Trailing 12-month operating profitability (RBOT.WS N/A vs STE 19.2%) and valuation multiples (RBOT.WS N/M vs STE 23.1x Forward P/E) are benchmarked directly in Pillar 4 below.

RBOT.WS ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
STE ADR TTM Benchmark FX-Normalized USD
TTM Revenue$6.17B
Gross Margin44.3%
Op. Margin19.2%
ROE / Fwd P/E11.6% · 23.1x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RBOT.WS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RBOT.WS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
STE SURGE
5d in phase · OBV DISTRIBUTION
Current IV 30.0%
IV Percentile 7th %ile
Put/Call OI Skew 4.50x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact STE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RBOT.WS Moat Profile Cyclical / Execution-Driven Positioning
Orthopedic, Prosthetic & Surgical Appliances & Supplies Operator
Competes within the Orthopedic, Prosthetic & Surgical Appliances & Supplies value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
STE Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $24.7B market capitalization and 19.2% operating margin.
OpEx & R&D Reinvestment 25.1% of Rev ($1.55B)
90D Engineering Disclosures 0 Published

Investor FAQ RBOT.WS vs STE Key Questions & Quantitative Answers

As of Nov 20, 2026, STERIS plc (STE) is the stronger overall head-to-head candidate over Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of (RBOT.WS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RBOT.WS carries a Unified Composite Score of 50.1/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin), whereas STE carries 42.6/100 (HOLD) at $255.76 (23.1x Forward P/E, 19.2% operating margin). Composite vs. Pillar Nuance: While RBOT.WS currently prints a higher short-term Unified Composite Score (50.1/100 HOLD vs. STE 42.6/100 HOLD), STE captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (19.2% vs. N/A operating margin) and revenue trajectory (+8.8% vs. N/A YoY).

STE leads the Growth & Scale pillar: RBOT.WS posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with STE at +8.8% YoY revenue growth and +12.9% YoY earnings growth on $6.17B TTM revenue (44.3% gross margin, 19.2% operating margin). On trailing 12-month operating scale, RBOT.WS generates N/A in USD-normalized revenue versus $6.17B for STE. In operating R&D and SG&A reinvestment, RBOT.WS deploys N/A (0 90-day corporate R&D disclosures) versus 25.1% of Rev ($1.55B) (0 disclosures) for STE.

STE screens cheaper on headline valuation multiples. RBOT.WS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas STE trades at 23.1x Forward P/E, 30.2x Trailing P/E, 2.53x PEG, and 4.3x EV/Revenue (15.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RBOT.WS (N/A ROE) versus STE (11.6% ROE) capital efficiency.

In options market volatility and institutional positioning, RBOT.WS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk). By comparison, STE carries 30.0% implied volatility (7th %ile, Compressed (<25th %ile)), a 4.50x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.18β · 35% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of Class A Common Stock at an exercise price of $345.00 (RBOT.WS) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.